الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 134 |  |  |
| | | from | 134 | | |
Abstract
Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of Non-Hodgkin Lymphoma (NHL). Genetic studies have revealed that one of its molecular subtypes resistant to treatment by standard protocols occurs when there are concurrent translocations in the C-MYC and BCL2 or BCL6 genes constituting the type known as double hit lymphoma (DHL). Double expresser lymphoma (DEL) is another subtype that is much more frequent than DHL, including about 20-30% of DLBCL cases. It occurs when there is protein overexpression of C-MYC together with BCL2 or BCL6 proteins without actual gene translocation. Both DEL and DHL has been linked in literature to inferior response, poor prognosis and worse outcomes.
In this study, we aimed to detect the presence of dual-protein expression in patients diagnosed with DLBCL at Clinical Oncology Department in Menoufia University Hospitals. We also aimed to explore the possible associations between C-MYC, BCL2 and/or BCL6 co-expression (DEL) and clinical as well as epidemiological data of included patients.
A tissue microarray platform was constructed using cores from selected areas of each specimen. Two mm diameter cores were duplicated and spaced each 2 mm. Several four-micron thick sections were prepared from formalin-fixed paraffin embedded blocks. Hematoxylin and Eosin slides were reviewed.